Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|December 1, 2023
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M Llovet, Masatoshi Kudo, Philippe Merle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 TrialGontran Verset, Ivan Borbath, Mark Karwal, et al.
The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology|November 10, 2020
Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focusJean-Philippe Metges, Jean-Yves Douillard, Jean-François Ramée, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2020
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 24, 2022
FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancerViolaine Randrian, Simon Pernot, Karine Le Malicot, et al.
Eclinicalmedicine|April 23, 2026
Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patientsBoris Guiu, Clément Bailly, Eric Vibert, et al.
Clinics and Research in Hepatology and Gastroenterology|February 21, 2022
MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancerEmeric Boisteau, Alexandra Lespagnol, Marie De Tayrac, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 25, 2022
Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert studyJules Gregory, Lambros Tselikas, Caroline Allimant, et al.
Pageof 16